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doi:10.101Rabbit Anti T-Lymphocyte Globulin Induces Apoptosis
in Peripheral Blood Mononuclear Cell Compartments
and Leukemia Cells, While Hematopoetic Stem Cells
Are Apoptosis Resistant
Carsten Gru¨llich,1,2 Christian Ziegler,1 Ju¨rgen Finke1Polyclonal anti-T-lymphocyte globulins (ATG) are used in allogeneic stem cell transplantation (SCT) for the
prophylaxis of graft versus host disease (GVHD) by in vivo T cell depletion. In this study we investigated the
complement independent induction of apoptosis by rabbit ATG in peripheral blood mononuclear cell
(PBMNC) compartments and hematopoetic stem cells (HSC). We also detected antileukemic activity of
ATG by measuring apoptosis in myeloid and lymphatic leukemia cell lines and primary leukemia cells. We
found ATG to induce apoptosis in T-lymphocytes (CD41, CD81), B-lymphocytes (CD201), natural killer
(NK)-cells (CD561), and monocytes (CD141). HSC, in contrast, were apoptosis resistant and could be
growth stimulated by low-dose ATG in the presence of bystander cells. The human leukemia cell lines Jurkat,
Daudi, DG-75 (lymphoblastic), and K562, HL-60, KG1, and U937 (myeloblastic) underwent ATG-induced
apoptosis, whereas the NK-cell line YTwas resistant. Primary leukemia cells from 6 investigated patients
with acute lymphoblastic leukemia, 9 of 10 patients with chronic lymphocytic leukemia, and 4 of 8 patients
with acute myeloblastic leukemia underwent ATG-induced apoptosis. We conclude apoptosis induction in all
PBMNC compartments contributes to GVHD prophylaxis. ATG might support engraftment. Finally, antileu-
kemic activity of ATG could positively influence the transplantation outcome.
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The use of anti-T-lymphocyte globulins (ATG) in
transplantation is established for the prevention of graft
rejection in organ transplantation or graft-versus-host
disease (GVHD) in allogeneic stem cell transplantation
(SCT) [1,2]. A variety of ATGs differing in immunogen
source and host species are currently in clinical use [3].
Their immunosuppressive action is thought to be
mainlymediated byT-lymphocyte depletion.However,
other peripheral blood mononuclear cell (PBMNC)
compartments, especially B-lymphocytes and mono-
cytes, are also involved in rejection and GVHD. ATG1Albert Ludwigs-University Medical Center Freiburg,
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complement-independent surface protein crosslinking
mediated apoptosis [4-7]. Because various surface anti-
gens that act as epitopes for ATG have been identified
to date including nonlineage-specific antigens, binding
of ATG to cells of non-T-lymphocyte lineage could
be demonstrated in several studies [8,9]. Also, apoptosis
in B-lymphocyte cell lines was previously shown to be
inducible by ATG [5]. In this study we provide data
showing the induction of complement-independent
apoptosis of rabbitATG-Fresenius,which is generated
against Jurkat leukemia cells, in the T-lymphocyte,
B-lymphocyte, monocyte, and natural killer (NK)-cell
compartment of primary PBMNC.
In SCT, repopulation of the bone marrow is facili-
tated by hematopoetic stem cells (HSC). Hence,
apoptosis of HSC would not be a desirable action of
ATG. Binding of ATG to HSC has been demonstrated
before [10] in patients with aplastic anemia.We investi-
gated the sensitivity of healthy HSC to ATG and found
HSC to be resistant to ATG-induced apoptosis. In con-
trast, ATG stimulated healthy HSC growth in methyl
cellulose stem cell cultures at low concentrations as pre-
sumably maintained over longer periods in the bone
marrow.173
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nizing against the human leukemia cell line Jurkat, we
studied the apoptosis-inducing activity of ATG against
leukemia cells. In the lymphoblastic cell lines Jurkat,
Daudi, DG-75, YT, and the myeloblastic cell lines
K562, HL-60, KG1, and U937, a dose-dependent ro-
bust apoptotic response to ATG could be observed.
In primary leukemia cells we found cells from all 6
patients with acute lymphoblastic leukemia (ALL), 9
of 10 patients with chronic lymphocytic leukemia
(CLL), and 4 of 8 patients with acute myeloblastic leu-
kemia (AML) to be responsive to apoptosis induction
by ATG. In conclusion, we provide evidence that
ATG has differing activity on all nonmalignant and
malignant mononuclear cell populations of hemato-
poetic origin inducing apoptosis in the cell compart-
ments involved in GVHD as well in many leukemia
cells, whereas HSC are growth stimulated. Taken
together, these data support the theory that ATG is
beneficial in SCT for leukemia by more effects than
mere T-lymphocyte depletion.MATERIALS AND METHODS
Patients and Healthy Volunteer Donors
Cells were collected from patients and healthy do-
nors who provided written consent for cell banking
and in vitro studies. The study was approved by the in-
ternal review board. Included into this study were leu-
kemic cells from 10 patients with CLL, 6 patients with
ALL, 8 patients with AML, leukapheresis samples
from 12 healthy stem cell donors, and PBMNC from
2 healthy volunteer donors.
Antibodies and Reagents
Rabbit ATG was from Fresenius, Graefelfing,
Germany. All fluorescence conjugated antibodies
were from BD Pharmingen, Franklin Lakes, NJ. Mag-
netic bead conjugated antibodies were from Miltenyi,
Bergisch-Gladbach, Germany. The Annexin V, PI
apoptosis kit was from R&D Systems, Wiesbaden,
Germany; all other reagents, unless otherwise indicated,
were from Sigma, St. Louis, MO.
Cell Culture
Cell lines were maintained in RPMI 1640 supple-
mented with 10% complement inactivated fetal calf se-
rum (FCS) nonessential amino acids, L-glutamine,
sodium pyruvate, 50 IU/mL penicillin, and 50 mg/
mL streptomycin (all from Gibco Life Technology,
Scotland, UK). Cells were kept in a humidified atmo-
sphere containing 5% CO2 at 37
C. All apoptosis ex-
periments were performed in this media. All cell
lines were from ATCC (Rockville, MD). Primary leu-
kemic cells from peripheral blood were isolated usingFicoll hypaque density centrifugation. Their lineage
specific surface markers were determined by routine
immunofluorocytometry. Hematopoetic stem cells
were from leukapheresis products from healthy stem
cell donors.
PBMNC—Compartment and Stem Cell
Separation
For magnetic cell separation T-lymphocytes,
monocytes, B-lymphocytes, NK-cells from PBMNC,
and HSC from leukapheresis products were purified
by positive selection for CD41, CD81, CD141,
CD191, CD561, and CD341, respectively, with the
Mini-MACS column magnetic cell sorting system
(Milteny, Bergisch-Gladbach, Germany) according to
manufacturers protocol. Briefly, 1 107 cells were sus-
pended in 80 mLof labeling buffer (PBS, EDTA2mM,
BSA 0.5%). Magnetically labeled antibody was added
20 mL each. The cells were incubated for 15 minutes
at 4C. The cells were washed in labeling buffer. The
resulting pellet was resuspended in 500 mL labeling
buffer and transferred onto a MACS column placed
in the MiniMACS magnet. For positive selection the
column fraction was collected. To increase purity the
separation was repeated once. Cell purity testing was
performedwith Phycoerythrin (PE)-labeled antibodies
against the corresponding CD markers.
ATG Binding
For binding studies of ATG-Fresenius 0.5  106
magnetically selected cells were incubated with 20
mg/mL ATG for 20 minutes at room temperature,
then washed twice with PBS and resuspended in 100
mL PBS with 1% BSA. Negative controls were treated
with 20 mg/mL preimmune rabbit IgG (Santa Cruz
Biotechnology, Santa Cruz, CA). Secondary antibody
labeling was performed with 5 mL of FITC-conjugated
goat antirabbit IgG (Cayman, Ann Arbor, MI) for 30
minutes at 4C. Cells were washed twice and analyzed
by fluorescence cytometry. Binding of ATG to unse-
lected PBMNC, HSC, and leukemia cells was per-
formed as above. Cells were double stained with
lineage-specific PE-labeled antibody and FITC goat
antirabbit IgG. Single dye-stained cells were used for
double color compensation. Binding to leukemia cell
lines was confirmed by single color staining with
FITC antirabbit IgG. In all fluorescence cytometry as-
says 10,000 cells were counted.
Apoptosis in PBMNC, HSC, and Leukemia Cells
To measure apoptosis induction of ATG 1  106/
mL cells were incubated with the indicated concentra-
tions of ATG (20 mg/mL to 1000 mg/mL) or preim-
mune rabbit IgG for controls (Santa Cruz
Biotechnology, Santa Cruz, CA) in cell culture media
and analyzed at several time points (3-24 hours) by
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PBMNC compartments, HSC, and primary leukemic
cells after incubation with ATG, cells were triple
stained with PE-conjugated lineage-specific antibody
as described and FITC-conjugated Annexin V and
Propidium-iodide (PI) according to manufacturers
instructions. Briefly, after incubation with ATG in
complement-inactivated RPMImedia cells were resus-
pended in 100 mL PBS stained with 5mL PE labeled
lineage antibody and incubated for 20 minutes at
room temperature. Then, cells were washed and resus-
pended in 100 mL AnnexinV binding buffer as pro-
vided by the manufacturer, 1 mL FITC-Annexin V
and 10 ng/mL PI were added, then cells were analyzed
by fluorescence cytometry. PE was detected in channel
2, FITC in channel 1, and PI in channel 3. Single
colors were used for color compensation. For analysis
cells were gated on their respective positive lineage
marker. AnnexinV and PI positivity was then assessed
according to the gate. Apoptotic cells were defined as
Annexin V single positive (early apoptosis) and An-
nexin V/PI double postive (late apoptosis). Vital cells
in HSC were defined as negative for AnnexinV/PI.
In leukemic cell lines apoptosis was additionally ana-
lyzed by measuring loss of mitochondrial membrane
potential (MMP) Dc with the green fluorescent dye
DiOC6 (3,30dihexicyloxacarbocyanine iodide) as de-
scribed [11]. DiOC6was added at a final concentration
of 0.5mmol to the cell suspension, incubated for 15
minutes at 37C and analyzed flow cytometrically. In
all fluorescence cytometry assays 10,000 cells were
counted.HSC—Colony Assay
To investigate the sensitivity of stem cells to ATG
for a longer period of timewe used a colony assay. Stem
cells from 9 different leukapheresis products were
plated on Petri dishes filled with methyl cellulose to al-
low growth of colonies of stem cells. Briefly, small Petri
dishes were filled with 2.1 mL of a methyl cellulose-
solution (21 g of methylcellulose [Methocel from
Fluka, Buchs, Switzerland] solved in 500 mL distilled
water and 500 mL IMDM-Medium), 0.9 mL BSA,
and 1 mg/mL GM-CSF (Cellgenix, Freiburg, Ger-
many). ATG or control rabbit IgGwas added to dishes
as indicated. Cells from leukapheresis products were
plated at 1.5 105 cells/mL and incubated for 2 weeks
at 37C. Then, dishes were scanned for colony growth
under a microscope; more than 30 cells on a defined
point were counted as a colony. To investigate if cells
other than HSC in the leukapheresis products have
an influence on colony growth of HSC we performed
the same experiment with stem cells magnetically
sorted for CD34 from 2 different donors plated at 5
 103 and 15  103 cells/mL each.Data Analysis
All experiments were performed, unless otherwise
noted, at least 2 times and in duplicate. To have com-
parable results of the apoptotis studies the specific
cytotoxicity in % was calculated by following formula:
specific cell death 5 (cell death[treated]2 cell death[-
control]/100 2 cell death[control])  100. Statistical
analysis was performed by 1-way analysis of variance
(ANOVA).RESULTS
ATG Binds to All PBMNC Compartments
Rabbit ATG binds to the surface of all PBMNC
compartments. We first incubated unseparated
PBMNC with ATG in increasing concentrations.
We found ATG to bind to PBMNC in a dose-depen-
dent manner. Figure 1A shows logarithmical increase
of fluorescence intensity of antibody bound to
PBMNC with increasing concentrations of ATG. To
confirm the binding of ATG to blood cell compart-
ments PBMNC were positively separated by magnetic
activated cell sorting (MACS) for CD4, CD8, CD20,
CD14, and CD56 to a purity of $90%, incubated
with ATG 20 mg/mL for 20 minutes, and stained
with FITC conjugated antirabbit IgG antibody.
Figure 1B shows the binding of ATG to all purified
PBMNC compartments. Alternatively, whole
PBMNC were incubated with ATG, stained with
FITC antirabbit IgG, and costained with the respec-
tive PE conjugated antihuman CD antibody. As shown
in Figure 1C, the respective cell compartments were
completely positive for ATG binding.
ATG Induces Apoptosis in PBMNC
Compartments
We investigated apoptosis induced in cell compart-
ments by triple-color fluorescence cytometry to avoid
a possible influence of the MACS sorting process on
apoptosis. The PBMNC were incubated with ATG at
differing concentrations and incubation times. The
cell compartments were stained with the lineage-spe-
cific PE conjugated antibodies. For apoptosis detection
Annexin V/PI staining was performed and analyzed for
the lineage specificmarker gate.We found that apopto-
sis was induced in all cell compartments already at
ATG concentrations of 20 mg/mL (not shown) with
a dose- and time-dependent increase of apoptosis
rate. Maximum apoptosis was seen at ATG 250 mg/
mL. Figure 2 depicts the lineage specific apoptosis
rate with ATG 250 mg/mL at 6 and 24 hours by An-
nexin V/PI staining. The time curve for apoptosis of
PBMNC compartments treated with ATG 250 mg/
mL from 3 to 24 hours is shown in Figure 3. Interest-
ingly, B-lymphocytes and monocytes showed a higher
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Figure 1. Binding of ATG to PBMNC compartments. Unseparated PBMNC were incubated with the indicated concentrations of ATG (X-axis is de-
picted in 2 sectors, left sector range: 0 to 3 mg/mL, right sector range: 10 to 250 mg/mL) for 20 minutes, stained with FITC-labeled antirabbit IgG, and
analyzed by fluorocytometry. Binding is expressed as mean fluorescence intensity (A). CD4-, CD8-, CD20-, CD14-, and CD56-positive selected cells
(purity$90%) were incubated with ATG 20 mg/mL for 20 minutes and stained with FITC antirabbit IgG (filled histograms) versus incubation with rabbit
IgG isotype control (open histograms) (B). Double staining with PE-labeled anti-CD antibodies and FITC antirabbit IgG after incubation of unseparated
PBMNC with ATG 20 mg/mL confirms the complete ATG binding of PBMNC compartments (C).
176 Biol Blood Marrow Transplant 15:173-182, 2009C. Gru¨llich et al.sensitivity to apoptosis than T-lymphocytes. Because
the important role of antigen presenting cells in the
pathogenesis of GVHD has become established and
evidence for some role for B-lymphocytes in chronic
GVHD (cGVHD) is also emerging, these data indicate
that the activity of ATG for GVHD prevention is not
limited to T-lymphocyte depletion, but might include
depletion of B-lymphocytes and monocytes. NK-cells,
in contrast, appear to be more apoptosis resistant.
HSC Are Resistant to ATG-Induced Apoptosis
Healthy HSC treated with pharmacologicaly rele-
vant doses of ATG were higly resistant to apoptosis.
Figure 4A confirms the binding of ATG to CD34-
positive HSC. We investigated unseparated HSC from
leukapheresis products of healthy human stem cell do-
nors for their sensitivity to apoptosis. To induce signif-
icant apoptosis in CD341 HSC high concentrations of
ATG above 500 mg/mL were required as shown in
Figure 4B for a 24-hour incubation time. Figure 4C
shows the rate of vital Annexin/PI negative CD341
HSC following incubation with the indicated concen-
trations of ATG for 6 and 24 hours. Again, a significant
declineof vital cells could onlybeobserved at concentra-tions above 500 mg/mL, that are not pharmacologically
relevant [12]. This observation is in accordance with the
clinical experience that ATGdoes not hamperHSC en-
graftment.
Low-Dose ATG Stimulates HSC Colony Growth
A growth stimulatory effect of horse ATG onHSC
of aplastic anemia patients has been demonstrated be-
fore [10,13]. To investigate if rabbit ATG could stim-
ulate the growth of healthy HSC, we performed
methylcellulose colony growth assays with 9 unsepa-
rated leukapheresis products of healthy volunteer do-
nors in the absence or presence of ATG at different
concentrations. We found low-dose ATG to stimulate
colony growth. In the presence of ATG 20 mg/mL sig-
nificantly more colonies could be observed at 14 days
(Figure 5A) compared to controls without ATG (P\
.0013). However, a concentration of 250 mg/mL abro-
gated colony growth completely. We further found
growth stimulation to be bystander cell dependent, be-
cause colony growth stimulation by low-dose ATG
was not observed in CD34 positively selected cells
from 2 donors seeded at 2 different cell concentrations
(Figure 5B).
Figure 2. ATG induces apoptosis in PBMNC compartments. PBMNC incubated with ATG 250 mg/mL for 6 h and 24 h were analyzed by triple-color
fluorescence for the lineage specific marker (PE anti CD) and Annexin V/PI staining for apoptosis detection. AnnexinV/PI plots represent the gate (R1) of
the indicated CD marker.
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Myeloblastic Leukemia Cell Lines
Because rabbit ATG is generated against Jurkat
cells, we hypothesized a potential antileukemic activity
of ATG. Apoptosis induction by ATG was investi-
gated in human leukemia cell lines. To confirm the
data obtained by Annexin V/PI doublestaining we
also performed MMP assays monitoring the mito-
chondrial stage of apoptosis. Figure 6 shows apoptosis
induced by ATG 250 mg/mL in HL-60 cells after 6
hours detected by Annexin V/PI (A) and MMP (B) as-
says.We found ATG to induce high levels of apoptosis
in the human lymphoblastic cell lines Jurkat, Daudi,
DG-75 (Figure 6C), and myeloblastic cell lines
K562,HL-60, KG1, andU937 (Figure 6D) at pharma-
cologically relevant ATG concentrations. Only the
human NK-cell leukemia line YT was resistant to
ATG-mediated apoptosis. The results obtained by
MMP closely matched those obtained by Annexin V/
PI presented in the figure (data not shown). This
indicates at the involvement of the mitochondrial
pathway of apoptosis in ATG-mediated cell death.
Although the response of cell lines of the lymphaticlineage was less surprising because ATG is generated
against a lymphatic cell line, the high sensitivity of
myeloblastic cell lines was much less expected by us.
ATG Induces Apoptosis in Primary Leukemia
Cells
Toaddress thequestion ifATGmightbe involved in
the killing of primary leukemia cells in the courseof con-
ditioning therapy we investigated the binding and apo-
ptosis inducing activity of ATG on leukemia cells of
10 patients with B-cell CLL, 6 patients with ALL, and
8 patients with AML. Following incubation with ATG
250 mg/mL for 24 hours, leukemia cells were stained
for their lineage-specific marker with PE-coupled anti-
body (CD 19 for CLL and B-ALL; CD34 for 2 patients
with precursor ALL; CD3 for 1 patient with T-ALL;
CD33, CD34, or CD117 for AML), and binding was
confirmed to all investigated cells with FITC antirabbit
IgG (data not shown). Similarly, apoptosis was investi-
gated by triple staining for lineage marker and Annexin
V/PI for apoptosis. Figure 7 shows the apoptosis rates of
all investigated primary leukemia cells treated with
ATG. Except for 1 patient who did not respond,
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Figure 3. Time course of ATG-induced apoptosis in PBMNC compartments. Time-dependent apoptosis rates as analyzed by AnnexinV/PI positivity of
PBMNC cell compartments incubated with ATG 250 mg/mL from 3 hours to 24 hours. Values represent mean 6 SEM from 2 experiments.
178 Biol Blood Marrow Transplant 15:173-182, 2009C. Gru¨llich et al.leukemia cells of 9 of 10CLL patients did undergo high
rates of apoptosis uponATG treatment (Figure 7A); ap-
optosis in leukemia cells was inducible in all 6 patients
with ALL, albeit in 2 patients at a very low rate0
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(Figure 7C). This observation differs from the results
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Figure 5. Colony growth of HSC in the presence of ATG. Unseparated
leukapheresis products of 9 healthy HSC donors were plated at 1.5 
105 cells/mL in methylcellulose as described. ATG was added at 20 mg/
mL and 250 mg/mL. Significantly (P\.0013) more colonies (CFU) could
be observed at 14 days in the culture with ATG 20 mg/mL, whereas ATG
250 mg/mL abrogated colony growth (mean: solid bars) (A). In HSC pos-
itively selected for CD34 no growth stimulation by ATG could be ob-
served. CD34 selected HSC of 2 healthy donors were plated at 5 
103 cells/mL (open symbols; mean: dotted bars) and 15  103 cells/mL
(filled symbols; mean: solid bars) in the presence of the indicated ATG
concentrations. At 14 days colony growth was reduced with both
ATG concentrations (B).
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proper apoptosis transduction, lack downstream effec-
tors required for apoptosis signal transduction, or third,
do overexpress factors that directly facilitate resistance.
However, ATG seems to have pro-apoptotic activity
against amajority of primary leukemia cells, particularly
those of lymphatic origin.DISCUSSION
Our study investigated the induction of apoptosis
in nonmalignant andmalignant mononuclear cell pop-
ulations by rabbit ATG generated against Jurkatlymphoblastic leukemia cells. We found ATG to
have a broad complement-independent apoptosis-
inducing activity to the cell compartments of human
PBMNC. Obviously, a wide spectrum of different an-
tibody specificities is present in the ATG preparation
generated against antigens shared between Jurkat cells
and the different PBMNC cell subsets. At present,
a few of these antigens have been specified, such as
CD11a, CD18, CD50, CD54, CD58, CD102,
CD40, CD45, HLA-DR, or chemokine receptors
CXCR4, CC5, CCR7 [14,15]. Our study shows that
crosslinking of cell surface antigens on all PBMNC
compartments induces signal transduction dependent
apoptosis. According to the current model of
GVHD, the non-T-lymphocyte PBMNC compart-
ments are also involved in the pathopysiology bymain-
taining inflammation and tissue damage. Interestingly,
we found the strongest activity of ATG to be against
B-cells andmonocytes. The crucial role of antigen pre-
senting cells (APC) in the initiation of acute GVHD
has long been recognized; hence, monocyte depletion
by ATG would be contributing to the prevention of
GVHD [3,16-18]. B-cells in contrast have only re-
cently been implicated in the pathophysiology of
chronic GVHD [19,20]. The weakest activity of
ATG in our study was shown to be against NK-cells.
Recent data show that NK-cells appear to have a rather
protective role against GVHD and a crucial role in the
development of a graft-versus-leukemia reaction
(GVL) [21-23]. Hence, the relative resistance of
NK-cells to apoptosis by ATG would be a rather ben-
eficial toward HSC outcome.
The activity of horse ATGs on HSC of patients
with aplastic anemia (AA) has been investigated in
a couple of studies [10,24,25]. Killick et al. [24] found
a reduction of spontaneous apoptosis in HSC from AA
patients treated with ATG.We found healthy HSC to
be highly resistant to rabbit ATG-mediated apoptosis.
One study also reported the stimulation of HSC col-
ony growth by low-dose horse ATG in healthy donors
and some patients with AA and myelodysplasia [26].
However, that study used CD341 selected cells. We,
in contrast, detected colony growth stimulation by
low doses of rabbit ATG only in the presence of by-
stander cells, indicating that rabbit ATG presumably
acts on HSC by a different mechanism requiring the
secretion of stimulatory cytokines [27]. Further, the
presence of high ATG concentrations abrogated
HSC colony growth. One possible explanation for
this might be ATG induced apoptosis of bystander
cells. However, the colony growth-inhibitory effect
of high ATG concentrations also observed in CD341
selected cells indicates at a direct antiproliferative ac-
tion of ATG at high doses during longer term culture.
A hypothetic mechanism could be the blockage of
growth factors and their receptors. In vivo, the concen-
trations of ATG have been found to be above 100 mg/
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Figure 6. ATG induces apoptosis in leukemia cell lines. HL-60 cells incubated with ATG 250 mg/mL for 6 hours show high rates for Annexin V/PI pos-
itivity (A) and comparable MMP as measured by loss of DJ (reduced DIOC6 uptake) (B). Concentration-dependent induction of apoptosis by ATG in
myeloblastic cell lines KG1, K562, HL-60, and U937 (C) and lymphoblastic cell lines Jurkat, Daudi, DG 75, and YT (D) after incubation with the indicated
concentrations of ATG for 6 hours by Annexin V/PI staining (mean 6 SEM from 2 independent experiments).
180 Biol Blood Marrow Transplant 15:173-182, 2009C. Gru¨llich et al.mL for about 24 hours following the final infusion and
than drop into a range between 10 to 50 mg/mL, at
which they aremaintained for the next 2 weeks [12], in-
dicating that HSC will be exposed to low-dose ATG
during most of the time preengraftment.
Because many of the known epitopes targeted by
ATG are also expressed on malignant cells, we postu-
lated activity against leukemia cells. Ayuk et al. [28]
demonstrated activity of horse ATG against myeloma
cells, albeit at concentrations twice as high as used in
our study. We found that anti-Jurkat rabbit ATG has
pro-apoptotic activity on leukemia cells regardless of
the originating lineage. We found a strong apoptotic
activity against cell lines of the myeloid and lymphatic
lineage.Only the humanNK-cell leukemia derived line
YT was shown to be resistant to ATG. Interestingly,
this correlates to the relative resistance of healthy
NK-cells. In primary leukemia cells the response rate
to apoptosis by ATG varied individually. Generally,
the strongest pro-apoptotic activity could be demon-
strated against CLL cells. However, in 1 of 10 patients
with CLL the leukemia cells were completely resistant.
Leukemia cells from all 6ALLpatients were responsive
to ATG at different rates, whereas leukemia cells from
4 of 8 patients with AML were also resistant to ATG
induced apoptosis. It is of note that this activity
was observed at concentrations of ATG that arepharmacologically reached during ATG infusion
[12]. Although these differential response rates were
observed for signal transduction-induced apoptosis,
there is no evidence for similar effects in comple-
ment-dependent lysis induced by ATG, which
proceeds in all cell types at very rapid kinetics provided
the presence of high concentrations of ATG and
complement [7,28].
In conclusion, we demonstrate that ATG acts on
a broad range of malignant and nonmalignant hemato-
poetic cells. Its activity is not limited to T cell deple-
tion, but apoptosis induction in monocytes and B
cells could contribute to the prevention of acute
GVHD (aGVHD) and cGVHD. HSC are resistant
to the pro-apoptotic activity of ATG, and engraftment
might even be supported by growth stimulation with
low-dose ATG. Furthermore, antileukemic activity
of ATG could be an additive factor to conditioning
chemotherapy for the prevention of recurrences.ACKNOWLEDGMENTS
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Figure 7. ATG induces apoptosis in primary leukemia cells. Specific Apoptosis rates for primary leukemia cells from 10 patients with CLL (A), 6 patients
with ALL (B), and 8 patients with AML (C) incubated with ATG 250 mg/mL for 24 hours measured by triple fluorescence for leukemia lineage marker and
Annexin V/PI (mean from 2 experiments) (*apoptosis rate slightly below control).
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